Scientists test new eczema Drug's hidden effects on common pills
NCT ID NCT06686628
Summary
This study aims to understand how a new investigational drug for eczema, called amlitelimab, might change how the body processes other common medications. It involves about 23 adults with moderate-to-severe atopic dermatitis. Researchers will measure drug levels in the blood to see if amlitelimab affects the safety or effectiveness of a standard set of other drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2760001
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.